Press Release: Viz.ai Closes 2025 with Record Scale and Patient Impact Achieving Profitability in Its Healthcare Business while Accelerating Life Sciences Growth

The episode covers FDA authorization for Viz.ai’s artificial intelligence-based module for detecting hypertrophic cardiomyopathy. The FDA’s de novo nod creates a new regulatory category for cardiovascular machine learning-based notification software. Learn about how this module works as this AI-based technology garners regulatory approval.